These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22119591)

  • 41. Vector-mediated antibody gene transfer for infectious diseases.
    Schnepp BC; Johnson PR
    Adv Exp Med Biol; 2015; 848():149-67. PubMed ID: 25757620
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fc receptor but not complement binding is important in antibody protection against HIV.
    Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
    Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load.
    Hasselrot K; Bratt G; Hirbod T; Säberg P; Ehnlund M; Lopalco L; Sandström E; Broliden K
    AIDS; 2010 Jan; 24(1):35-43. PubMed ID: 19779318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Therapeutic use of immune sera. Ebola survivors as lifesavers?].
    Eickmann M; Schumacher B
    MMW Fortschr Med; 2014 Nov; 156(19):6. PubMed ID: 25509993
    [No Abstract]   [Full Text] [Related]  

  • 45. Prevention of HIV infection by passive immunization with HIV immunoglobulin.
    Prince AM; Reesink H; Pascual D; Horowitz B; Hewlett I; Murthy KK; Cobb KE; Eichberg JW
    AIDS Res Hum Retroviruses; 1991 Dec; 7(12):971-3. PubMed ID: 1812946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Report of the 2014 Cent Gardes HIV Vaccine Conference - Part 1: Neutralizing Antibodies; Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 October 2014.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2015 Jul; 33(31):3605-8. PubMed ID: 25769208
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters.
    Brandenberg OF; Magnus C; Rusert P; Günthard HF; Regoes RR; Trkola A
    PLoS Pathog; 2017 May; 13(5):e1006313. PubMed ID: 28472201
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Passive immunization against HIV/AIDS by antibody gene transfer.
    Yang L; Wang P
    Viruses; 2014 Jan; 6(2):428-47. PubMed ID: 24473340
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modeling HIV Dynamics Under Combination Therapy with Inducers and Antibodies.
    Yan C; Wang W
    Bull Math Biol; 2019 Jul; 81(7):2625-2648. PubMed ID: 31161559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Active and passive anticytokine immune therapies: current status and development.
    Le Buanec H; Bensussan A; Bagot M; Gallo RC; Zagury D
    Adv Immunol; 2012; 115():187-227. PubMed ID: 22608260
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chief Science Officer of IAVI departs to lead Human Vaccines Project.
    Kresge KJ
    IAVI Rep; 2016; 20(1):14-5. PubMed ID: 27301166
    [No Abstract]   [Full Text] [Related]  

  • 52. Anti-idiotypic therapeutic strategies in HIV infection.
    Wilks D; Dalgleish AG
    Mol Cell Biol Hum Dis Ser; 1992; 1():283-308. PubMed ID: 1341647
    [No Abstract]   [Full Text] [Related]  

  • 53. Immunotherapeutics to Treat HIV in the Central Nervous System.
    Kapoor A; Tan CS
    Curr HIV/AIDS Rep; 2020 Oct; 17(5):499-506. PubMed ID: 32671567
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006.
    Bansal GP
    Biologicals; 2007 Oct; 35(4):367-71. PubMed ID: 17889555
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A case for passive immunoprophylaxis against tuberculosis.
    Reljic R; Ivanyi J
    Lancet Infect Dis; 2006 Dec; 6(12):813-8. PubMed ID: 17123901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Virological and immunological data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in HIV-1 antibodies).
    Morand-Joubert L; Vittecoq D; Roudot-Thoraval F; Mariotti M; Lefrère F; Heshmati F; Audat F; Lambin P; Barré-Sinoussi F; Lefrère JJ
    Vox Sang; 1997; 73(3):149-54. PubMed ID: 9358616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human monoclonal antibodies for passive immunotherapy of HIV-1.
    Katinger H
    Antibiot Chemother (1971); 1994; 46():25-37. PubMed ID: 7826037
    [No Abstract]   [Full Text] [Related]  

  • 58. Human Antibodies for Viral Infections.
    Crowe JE
    Annu Rev Immunol; 2022 Apr; 40():349-386. PubMed ID: 35113730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccinology: precisely tuned antibodies nab HIV.
    Clapham PR; Lu S
    Nature; 2011 Sep; 477(7365):416-7. PubMed ID: 21938063
    [No Abstract]   [Full Text] [Related]  

  • 60. The role of passive immunization in hiv-positive patients : a case report.
    Veljkovic V; Metlas R; Jevtovic D; Stringer WW
    Chest; 2001 Aug; 120(2):662-6. PubMed ID: 11502675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.